		Co	Complete if Known		
		Application Number	09/510,560		
M DISCLOSI	RF		February 22, 2000		
			Kenneth I. Cumming		
STATEMENT BY APPLICANT			1639		
anta na nanagan	d	Examiner Name	Jeffrey S. Lundgren		
	7)	Attorney Docket Number	9701-6		
	BY APPLICA	ON DISCLOSURE BY APPLICANT eets as necessary) of 2	Application Number Filing Date First Named Inventor Art Unit Examiner Name Atterney Deglet Number		

			U.S. PATENT DOC	UMENTS	
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
miliais"	INO.	Number-Kind Code (if known)		177	Figures Appear
	1	5,190,748	03-02-1993	Bachynsky et al.	
	2.	6,326,360 B1	12-04-2001	Kanazawa et al.	
	3.	2007/0292512 A1	12-20-2007	Leonard et al.	

		FO	REIGN PATENT DO	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.	Country Code, Number, Kind Code (if known)		Origa Boodinem	Passages or Relevant Figures Appear	T
	4.	EP 0370481 A2	11-21-1989	F. Hoffmann-La Roche AG		
	5.	EP 0376534 A1	07-04-1990	Riker Laboratories, Inc.		
	6.	EP 0580074 A1	01-26-1994	ASTA Medica Aktiengesellschaft and Eisai Co., Ltd.		
	7.	JP 2282327	11-19-1990	Riker Laboratories, Inc.		
	8.	JP 6040949	02-15-1994	Eisai Co., Ltd.		-
	9.	JP 11035458	02-09-1999	Teikoku Seiyaku KK		
	10.	JP 2004529953	09-30-2004			50
	11.	WO 93/05903 A1	04-01-1993	Hadley Industries PLC		
	12.	WO 93/21907	11-11-1993	Leiras Oy		
	13.	WO 99/02120 A2	01-21-1999	D-Pharm Ltd.		
	14.	WO 99/02485 A1	01-21-1999	D-Pharm Ltd.		
	15.	WO 99/45934 A1	09-16-1999	Grelan Pharmaceutical Co.		
	16.	WO 00/22909 A2	04-27-2000	Biotech Australia PTY. Limited		
	17.	WO 02/092070	11-21-2002	Elan Corporation, PLC		
	18.	WO 03/047493 A2	06-12-2003	DOR BIOPHARMA INC.		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
	19.	AUNGST, "Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants," Pharm. Res. 6:244-247 (1989)				
	20.	CHAN et al., "Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS," Invest. New Drugs 15:195-206 (1997).				
	21.	MISHIMA et al., "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats," J. Pharmacobio-Dyn., 10:624-631 (1987).				
	22.	MORISHITA et al., "Site-Dependent Effect of Aprotinin, Sodium Caprate, Na₂EDTA and Sodium Glycocholate on Intestinal Absorption of Insulin," Biol. Pharm. Bull. 16:68-72 (1993).				
	23.	SCHNEIDER et al., "Evaluation of drug penetration into human skin ex vivo using branched fatty acids and propylene glycol," Int. J. Pharm. 145:187-196 (1996)				
	24.	YAMAMOTO et al., "Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors," J. Control. Release, 41:57-67 (1996).				
kaminer gnature		Date Considered				

Signature | Considered |
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Complete if Known		
			Application Number	09/510,560	
INFORMATION DISCLOSURE				February 22, 2000	
				Kenneth I. Cumming	
STATEMENT BY APPLICANT			1639		
		1		Jeffrey S. Lundgren	
	····	1 2		9701-6	
ļ	MENT BY	mENT BY APPLICAN	ment by APPLICANT nany sheets as necessary)	Application Number Filing Date First Named Inventor Art Unit Examiner Name	

	25.	YANG et al., Deposition of insulin powders for inhalation in vitro and pharmacodynamic evaluation of absorption promoters in rats," Acta Pharmaceutica Sinica 40:1069-1074 (2005).	
and the second s	26.	ZHOU et al., "Effects of cholic acid and other enhancers on the bioavailability of insulin from a subcutaneous site," Int. J. Pharm. 69:29-41 (1991).	
	27.	Application No. 11/450,641; Filed: 06/09/2006; Office Action Mailed 6/25/2009	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.